0001209191-23-038847.txt : 20230621
0001209191-23-038847.hdr.sgml : 20230621
20230621172440
ACCESSION NUMBER: 0001209191-23-038847
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230616
FILED AS OF DATE: 20230621
DATE AS OF CHANGE: 20230621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Borgeson Blake
CENTRAL INDEX KEY: 0001856094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 231030900
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-16
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856094
Borgeson Blake
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
1
0
0
0
0
Class A Common Stock
2023-06-16
4
A
0
12612
0.00
A
7537874
D
Stock Option (Right to Buy
8.92
2023-06-16
4
A
0
25224
0.00
A
2024-06-16
2033-06-16
Class A Common Stock
25224
25224
D
Stock Option (Right to Buy)
6.20
2023-06-14
2032-06-14
Class A Common Stock
36290
36290
D
Stock Option (Right to Buy)
18.00
2022-04-15
2031-04-15
Class A Common Stock
12500
12500
D
Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer.
The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
/s/ Jonathan Golightly, attorney-in-fact
2023-06-21